Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P07737: Variant p.Cys71Gly

Profilin-1
Gene: PFN1
Feedback?
Variant information Variant position: help 71 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Glycine (G) at position 71 (C71G, p.Cys71Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In ALS18; the mutant protein is detected in the insoluble fraction of cells. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 71 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 140 The length of the canonical sequence.
Location on the sequence: help LVGKDRSSFYVNGLTLGGQK C SVIRDSLLQDGEFSMDLRTK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LVG--KDRSSFYVNGLTLGGQKCSVIRDSLLQDGEFSMDLRTK

Mouse                         LVG--KDRSSFFVNGLTLGGQKCSVIRDSLLQDGEFTMDLR

Rat                           LVG--KDRSSFFVNGLTLGGQKCSVIRDSLLQDGEFTMDLR

Bovine                        LVG--KDRSSFFVNGLTLGGQKCSVIRDSLLQDGEFTMDLR

Caenorhabditis elegans        FVALFNDVTQVPAKGADIEGVHYVVPR------TEESLIFG

Slime mold                    IAALFKNPAEVFAKGALIGGVKYMGIK------GDPQSIYG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 140 Profilin-1
Modified residue 57 – 57 Phosphoserine
Modified residue 85 – 85 Phosphoserine
Cross 54 – 54 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Cross 54 – 54 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Beta strand 69 – 77



Literature citations
Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis.
Wu C.H.; Fallini C.; Ticozzi N.; Keagle P.J.; Sapp P.C.; Piotrowska K.; Lowe P.; Koppers M.; McKenna-Yasek D.; Baron D.M.; Kost J.E.; Gonzalez-Perez P.; Fox A.D.; Adams J.; Taroni F.; Tiloca C.; Leclerc A.L.; Chafe S.C.; Mangroo D.; Moore M.J.; Zitzewitz J.A.; Xu Z.S.; van den Berg L.H.; Glass J.D.; Siciliano G.; Cirulli E.T.; Goldstein D.B.; Salachas F.; Meininger V.; Rossoll W.; Ratti A.; Gellera C.; Bosco D.A.; Bassell G.J.; Silani V.; Drory V.E.; Brown R.H. Jr.; Landers J.E.;
Nature 488:499-503(2012)
Cited for: VARIANTS ALS18 GLY-71; THR-114; GLY-117 AND VAL-118; CHARACTERIZATION OF VARIANTS ALS18 GLY-71; THR-114; GLY-117 AND VAL-118;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.